CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,003,800 | -27.7% | 370,000 | -56.2% | 3.58% | -1.7% |
| Q2 2023 | $15,226,900 | +20.6% | 845,000 | +7.5% | 3.64% | -3.7% |
| Q1 2023 | $12,622,742 | -5.8% | 785,794 | +7.3% | 3.78% | -18.8% |
| Q4 2022 | $13,395,600 | +1.6% | 732,000 | +9.0% | 4.66% | -14.5% |
| Q3 2022 | $13,184,000 | +5.3% | 671,300 | 0.0% | 5.44% | -3.5% |
| Q2 2022 | $12,520,000 | -17.7% | 671,300 | -3.1% | 5.64% | +19.5% |
| Q1 2022 | $15,211,000 | -26.1% | 693,000 | -4.3% | 4.72% | +8.2% |
| Q4 2021 | $20,580,000 | +143.1% | 724,400 | +80.1% | 4.36% | +176.1% |
| Q3 2021 | $8,464,000 | +124.0% | 402,113 | +100.6% | 1.58% | +151.8% |
| Q2 2021 | $3,779,000 | +31.5% | 200,500 | +6.6% | 0.63% | +48.8% |
| Q1 2021 | $2,873,000 | -23.6% | 188,000 | -21.7% | 0.42% | -42.7% |
| Q3 2020 | $3,761,000 | -50.7% | 240,000 | -44.9% | 0.74% | -52.2% |
| Q2 2020 | $7,625,000 | +40.7% | 435,200 | +18.0% | 1.54% | +7.2% |
| Q1 2020 | $5,421,000 | -18.8% | 368,750 | +38.6% | 1.44% | +9.7% |
| Q4 2019 | $6,676,000 | +114.5% | 266,100 | +28.6% | 1.31% | +16.3% |
| Q3 2019 | $3,113,000 | +245.9% | 207,000 | +475.0% | 1.13% | +310.9% |
| Q2 2019 | $900,000 | -45.8% | 36,000 | -50.7% | 0.27% | -40.4% |
| Q1 2019 | $1,661,000 | – | 73,000 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |